Maintenance chemotherapy in the management of epithelial ovarian cancer

被引：0
作者：
Maurie Markman
机构：
[1] Cancer Treatment Centers of America,College of Medicine
[2] Drexel University,undefined
来源：
Cancer and Metastasis Reviews | 2015年 / 34卷
关键词：
Epithelial ovarian cancer; Chemotherapy; Maintenance therapy; Paclitaxel; Anti-angiogtenic agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.
引用
收藏
页码：11 / 17
页数：6
相关论文
共 117 条
[21]  
Boice JD(2009)Detecting an overall survival benefit that is derived from progression-free survival Journal of Clinical Oncology 27 4642-4648
[22]  
Lambert HE(2004)Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol 1 Journal of Clinical Oncology 22 2635-2642
[23]  
Rustin GJ(2006)Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study Journal of the National Cancer Institute 98 1036-1045
[24]  
Gregory WM(2006)Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Intergroup trial of the AGO-AOVAR and GINECO International Journal of Gynecological Cancer 16 74-78
[25]  
Bertelsen K(2004)Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study International Journal of Gynecological Cancer 14 224-228
[26]  
Jakobsen A(2005)Long-term follow-up of a phase II trial of oral altretamine for consolidation of complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group Nature 438 967-974
[27]  
Stroyer J(2007)Angiogenesis as a therapeutic target Journal of Clinical Oncology 25 5165-5171
[28]  
Hakes TB(2007)Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study Journal of Clinical Oncology 25 5180-5186
[29]  
Chalas E(2011)Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer New England Journal of Medicine 365 2473-2483
[30]  
Hoskins WJ(2011)Incorporation of bevacizumab in the primary treatment of ovarian cancer New England Journal of Medicine 365 2484-2496
12345678910